Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

MAGE-A3 Promotes Chemotherapy Resistance and Proliferation in Multiple Myeloma through Regulation of BIM and p21 Cip1

Hearn Jay Cho, MD, Anna Huo-Chang Mei, MS, Kaity Tung, BS, Jessie Han, Deepak Perumal, PhD, Jonathan J Keats, PhD, Daniel Auclair, PhD, Ajai Chari, MD, Sundar Jagannath, MD, Samir Parekh, MD, Alessandro Lagana, PhD

Blood (2018) 132 (Supplement 1): 4464.

https://doi.org/10.1182/blood-2018-99-118692

Published: 2018

Journal Articles

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Chia-jen Liu, MD, Irene M. Ghobrial, MD, Mark Bustoros, MD, Kaitlen Reyes, NP, Kalvis Hornburg, BA, Ashraf Z. Badros, MD, James J. Vredenburgh, MD, Adam Boruchov, MD, Jeffrey V Matous, MD, Aaron Caola, BS, Bradley Rivotto, BS, Alexandra Savell, BS, Patrick Henrick, BS, Claudia E. Paba-Prada, MD, Robert L. Schlossman, MD, Jacob Laubach, MD, Jacalyn Rosenblatt, MD, Andrew J Yee, MD, Omar Nadeem, MD, Rodrigo O. Maegawa, MD, Andrzej Jakubowiak, MD PhD, Saad Z. Usmani, MD, Manisha Bhutani, MD, Joseph Cappuccio, BS, Brianna Berrios, BS, Kimberly Noonan, NP, Oksana Zavidij, PhD, Tarek H Mouhieddine, MD, Cody J Boehner, Carl-Jannes Neuse, Karma Ziad Salem, MD, Mairead Reidy, PhD, Jihye Park, PhD, Michael Agius, PhD, Mahshid Rahmat, PhD, Salomon Manier, MD PhD, Divaya Bhutani, MD, Jeffrey A Zonder, MD, Nikhil Munshi, MD, Daniel Auclair, PhD, Kenneth Anderson, MD, Paul Richardson

Blood (2018) 132 (Supplement 1): 154.

https://doi.org/10.1182/blood-2018-154

Published: 2018

Journal Articles

Functional Genomic Landscape of Genes with Recurrent Mutations in Multiple Myeloma

Ricardo De Matos Simoes, PhD, Ryosuke Shirasaki, MD PhD, Huihui Tang, PhD, Michal Sheffer, PhD, Olga Dashevsky, PhD, Sara Gandolfi, MD, Eugen Dhimolea, PhD, Megan Bariteau, BSc, Jonathan D. Licht, MD, Brian Glassner, PhD, Richard WJ Groen, PhD, Joan Levy, PhD, Daniel Auclair, PhD, Francisca Vazquez, PhD, Aviad Tsherniak, PhD, William C. Hahn, MD PhD, Aedin Culhane, PhD, Constantine S. Mitsiades, MD PhD

Blood (2018) 132 (Supplement 1): 189.

https://doi.org/10.1182/blood-2018-189

Published: 2018

Journal Articles

Development and Validation of a High Risk Multiple Myeloma Gene Expression Index from RNA Sequencing: An Mmrf Commpass Analysis

Daniel Penaherrera, BSc, Sheri Skerget, PhD, Austin Christofferson, BSc, Jessica Aldrich, Sara Nasser, PhD, Christophe Legendre, Martin Boateng, BS, Lori Cuyugan, Jonathan Adkins, Erica Tassone, Jennifer Yesil, MS, Daniel Auclair, PhD, Winnie Liang, PhD, Sagar Lonial, MD, Jonathan J Keats, PhD

Blood (2018) 132 (Supplement 1): 1895.

https://doi.org/10.1182/blood-2018-99-119610

Published: 2018

Journal Articles

Myeloma Patient-Derived MCL1 Point Mutations Can Influence MCL1-Inhibitor Function

Brandon Chen, Wong Pamela, B.S., Daniel Auclair, PhD, Jonathan J Keats, PhD, Paul Secrist, PhD, Justin Cidado, PhD, Adriana E. Tron, PhD, Christine M Dunham, PhD, Sagar Lonial, MD, Joseph Opferman, PhD, Shannon M Matulis, PhD, Lawrence H. Boise, PhD

Blood (2018) 132 (Supplement 1): 951.

https://doi.org/10.1182/blood-2018-99-113444

Published: 2018

Journal Articles

Patient Treatment Preferences for Relapsed/Refractory Multiple Myeloma: Are Patients Willing to Trade Off Efficacy for Tolerability?

Daniel Auclair, PhD, Carol Mansfield, PhD, Ajai Chari, MD, Craig E. Cole, MD, Mark A. Fiala, BS, Jonathan L Kaufman, MD, Gregory Orloff, MD, David S Siegel, MD PhD, Jeffrey A Zonder, MD, Brennan Mange, Jennifer Yesil, MS, Mehul Dalal, PhD, Joseph Mikhael, MD FRCPC, MD

Blood (2018) 132 (Supplement 1): 614.

https://doi.org/10.1182/blood-2018-99-113087

Published: 2018

Journal Articles

The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome

Blood (2018) 132 (Supplement 1): 749.

https://doi.org/10.1182/blood-2018-99-113059

Published: 2018

Journal Articles

Carfilzomib-Lenalidomide-Dexamethasone Versus Bortezomib-Lenalidomide-Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Results from the Prospective, Longitudinal, Observational Commpass Study

Ola Landgren, MD PhD, David S Siegel, MD PhD, Daniel Auclair, PhD, Ajai Chari, MD, Michael Boedigheimer, Tim Welliver, MD PhD, Khalid Mezzi, Karim Iskander, Andrzej Jakubowiak, MD PhD

Blood (2018) 132 (Supplement 1): 799.

https://doi.org/10.1182/blood-2018-99-112289

Published: 2018

Journal Articles

Immunoglobulin Lambda Translocations Identify Poor Outcome and IMiD Resistance in Multiple Myeloma and Co-Occur with Hyperdiploidy

Benjamin G Barwick, PhD, Paola Neri, MD, Nizar Bahlis, MD, Ajay K Nooka, MDMPH, Jonathan L Kaufman, MD, Vikas A. Gupta, MD PhD, Daniel Auclair, PhD, Jonathan J Keats, PhD, Sagar Lonial, MD, Paula M Vertino, PhD, Lawrence H. Boise, PhD

Blood (2018) 132 (Supplement 1): 405.

https://doi.org/10.1182/blood-2018-99-113585

Published: 2018

Journal Articles

Chromothripsis and Chromoplexy Are Associated with DNA Instability and Adverse Clinical Outcome in Multiple Myeloma

Blood (2018) 132 (Supplement 1): 408.

https://doi.org/10.1182/blood-2018-99-117359

Published: 2018

Journal Articles

An Integrated Genomics Analysis Identifies Recurrent Gain- and Loss-of-Function Events and in Distinct Subtypes of Multiple Myeloma

Sara Nasser, PhD, Jessica Aldrich, Daniel Penaherrera, BSc, Austin Christofferson, BSc, Christophe Legendre, Jennifer Yesil, MS, Daniel Auclair, PhD, Winnie Liang, PhD, Sagar Lonial, MD, Sheri Skerget, PhD, Jonathan J Keats, PhD

Blood (2018) 132 (Supplement 1): 113.

https://doi.org/10.1182/blood-2018-99-119354

Published: 2018

Journal Articles

Increased HLA-E Expression Correlates with Early Relapse in Multiple Myeloma

Blood (2018) 132 (Supplement 1): 59.

https://doi.org/10.1182/blood-2018-99-116828

Published: 2018

Journal Articles

Whole Genome DNA Methylation Analysis of Commpass Identifies Biomarkers of Multiple Myeloma Survival

Benjamin G Barwick, PhD, Daniel Auclair, PhD, Alex Blanski, Meghan Kirchhoff, Brianne Docter, Daniel C Rohrer, Jonathan J Keats, PhD, Sagar Lonial, MD, Lawrence H. Boise, PhD, Paula M Vertino, PhD

Blood (2018) 132 (Supplement 1): 3174.

https://doi.org/10.1182/blood-2018-99-116875

Published: 2018

Journal Articles

CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins: Implications for Novel Therapeutics across Diverse Neoplasias

Blood (2018) 132 (Supplement 1): 1367.

https://doi.org/10.1182/blood-2018-99-116232

Published: 2018

Journal Articles

Analysis of Sequential Patient Samples from the Mmrf Commpass Study Identifies a High Risk Progression Phenotype

Sheri Skerget, PhD, Daniel Penaherrera, BSc, Jessica Aldrich, Sara Nasser, PhD, Austin Christofferson, BSc, Christophe Legendre, Martin Boateng, BS, Lori Cuyugan, Jonathan Adkins, Erica Tassone, Jennifer Yesil, MS, Daniel Auclair, PhD, Winnie Liang, PhD, Sagar Lonial, MD, Jonathan J Keats, PhD

Blood (2018) 132 (Supplement 1): 111.

https://doi.org/10.1182/blood-2018-99-118617

Published: 2018

Journal Articles

Impact of Prior Cancer on Eligibility for Plasma Cell Disorder (PCD) Clinical Trials

Sandra Garcia, Olivia Dorsey, MSIS, Sandi Pruitt, PhD MPH, Saurabh Dahiya, MD, David Gerber, MD, Robert Frank Cornell, MD, Daniel Auclair, PhD, Robert H. Collins, MD, Steven Devine, Saad Z. Usmani, MD, Larry Anderson, MD PhD, Shaji K. Kumar, MD, Ankit Kansagra, MD

Blood (2018) 132 (Supplement 1): 2267.

https://doi.org/10.1182/blood-2018-99-113510

Published: 2018

Journal Articles

Comprehensive Identification of Fusion Transcripts in Multiple Myeloma: An Mmrf Commpass Analysis

Sara Nasser, Austin Christofferson, BS, Christophe Legendre, Jessica Aldrich, Brooks Benard, BS, The MMRF CoMMpass Network, Jennifer Yesil, MS, Daniel Auclair, PhD, Winnie Liang, PhD, Sagar Lonial, MD, Jonathan Keats, PhD

Blood (2017) 130 (Supplement 1): 61.

https://doi.org/10.1182/blood.V130.Suppl_1.61.61

Published: 2017

Journal Articles

Clonal Evolution in Newly Diagnosed Multiple Myeloma Patients: A Follow-up Study from the Mmrf Commpass Genomics Project

Alessandro Lagana, PhD, David Melnekoff, BS, MSc, Itai Beno, PhD, Violetta Leshchenko, PhD, Deepak Perumal, PhD, Jonathan J. Keats, PhD, Mary DeRome, MS, Jennifer Yesil, MS, Daniel Auclair, PhD, Deepu Madduri, MD, Ajai Chari, MD, Hearn Jay Cho, MD PhD, Bart Barlogie, MD PhD, Sundar Jagannath, MD, Joel Dudley, PhD, Samir Parekh, MD

Blood (2017) 130 (Supplement 1): 325.

https://doi.org/10.1182/blood.V130.Suppl_1.325.325

Published: 2017

Journal Articles

Integrative Analysis of the Genomic Landscape Underlying Multiple Myeloma at Diagnosis: An Mmrf Commpass Analysis

Austin Christofferson, BS, Sara Nasser, Jessica Aldrich, Daniel Penaherrera, Christophe Legendre, Brooks Benard, BS, Sheri Skerget, PhD, The MMRF CoMMpass Network, Jennifer Yesil, MS, Daniel Auclair, PhD, Winnie Liang, PhD, Sagar Lonial, MD, Jonathan Keats, PhD

Blood (2017) 130 (Supplement 1): 326.

https://doi.org/10.1182/blood.V130.Suppl_1.326.326

Published: 2017

Journal Articles

Understanding the Preferences of Patients and Caregivers for Relapsed/Refractory Multiple Myeloma Treatment: A Mixed-Mode Patient-Centric Approach

Daniel Auclair, PhD, Carol Mansfield, PhD, Ajai Chari, MD, Craig E. Cole, MD, Mark A. Fiala, BS, Jonathan L. Kaufman, MD, Gregory Orloff, MD, David Siegel, MD PhD, Jeff A. Zonder, MD, Brennan Mange, Jennifer Yesil, MS, Mehul Dalal, PhD, Joseph Mikhael, MD

Blood (2017) 130 (Supplement 1): 5662.

https://doi.org/10.1182/blood.V130.Suppl_1.5662.5662

Published: 2017

NARROW

MAGE-A3 Promotes Chemotherapy Resistance and Proliferation in Multiple Myeloma through Regulation of BIM and p21 Cip1

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Functional Genomic Landscape of Genes with Recurrent Mutations in Multiple Myeloma

Development and Validation of a High Risk Multiple Myeloma Gene Expression Index from RNA Sequencing: An Mmrf Commpass Analysis

Myeloma Patient-Derived MCL1 Point Mutations Can Influence MCL1-Inhibitor Function

Patient Treatment Preferences for Relapsed/Refractory Multiple Myeloma: Are Patients Willing to Trade Off Efficacy for Tolerability?

The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome

Carfilzomib-Lenalidomide-Dexamethasone Versus Bortezomib-Lenalidomide-Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Results from the Prospective, Longitudinal, Observational Commpass Study

Immunoglobulin Lambda Translocations Identify Poor Outcome and IMiD Resistance in Multiple Myeloma and Co-Occur with Hyperdiploidy

Chromothripsis and Chromoplexy Are Associated with DNA Instability and Adverse Clinical Outcome in Multiple Myeloma

An Integrated Genomics Analysis Identifies Recurrent Gain- and Loss-of-Function Events and in Distinct Subtypes of Multiple Myeloma

Increased HLA-E Expression Correlates with Early Relapse in Multiple Myeloma

Whole Genome DNA Methylation Analysis of Commpass Identifies Biomarkers of Multiple Myeloma Survival

CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins: Implications for Novel Therapeutics across Diverse Neoplasias

Analysis of Sequential Patient Samples from the Mmrf Commpass Study Identifies a High Risk Progression Phenotype

Impact of Prior Cancer on Eligibility for Plasma Cell Disorder (PCD) Clinical Trials

Comprehensive Identification of Fusion Transcripts in Multiple Myeloma: An Mmrf Commpass Analysis

Clonal Evolution in Newly Diagnosed Multiple Myeloma Patients: A Follow-up Study from the Mmrf Commpass Genomics Project

Integrative Analysis of the Genomic Landscape Underlying Multiple Myeloma at Diagnosis: An Mmrf Commpass Analysis

Understanding the Preferences of Patients and Caregivers for Relapsed/Refractory Multiple Myeloma Treatment: A Mixed-Mode Patient-Centric Approach

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only